Posted by Paul Nanuwa
at 4:44 PM on Wednesday, August 21st, 2024
Introduction:
As gold prices surge to record highs, driven by robust demand from China and favorable market conditions, companies in the mining sector are experiencing a renewed wave of investor interest. Among these, Stelmine Canada (STH: TSXV) (STHFF: OTCQB) stands out as a dynamic player in the gold exploration industry. With strategic projects in Northern Quebec and recent leadership enhancements, Stelmine is poised to capitalize on the market’s upward trajectory.
Industry Outlook and Stelmine Canada’s Trajectory
The gold market is on a bullish trend, with December Comex gold futures reaching unprecedented levels. This surge is bolstered by strong demand from China and a weakening U.S. dollar, creating a favorable environment for gold exploration companies. Stelmine Canada, with its focus on under-explored regions in Northern Quebec, is strategically positioned to benefit from this upward momentum. As global interest in gold continues to rise, Stelmine’s ongoing projects in the Caniapiscau district align perfectly with the current market dynamics.
Voices of Authority
Industry experts have highlighted the significance of China’s increasing demand for gold, noting how it has become a preferred instrument for savings amid economic uncertainty. This sentiment echoes the strategic direction of Stelmine Canada, as the company continues to explore and develop promising gold deposits in Quebec.
Ruth Crowell, CEO of the London Bullion Market Association recently commented, “There are lots of reasons driving gold right now…, but one of the major factors is China.” Crowell continued to say, “Usually China and Japan have been budget shoppers, but given the state of the economy, real estate challenges and equity markets, gold is a safe choice… I think gold is going to be of interest for some time.”
Stelmine Canada’s Highlights Within Stelmine’s portfolio, the Courcy Property emerges as a testament to the company’s commitment to innovation and discovery. Courcy embodies the spirit of exploration and potential, setting new standards for gold development in Northern Quebec. Courcy hosts Geological similarities to Newmont’s Eleonore mine (Gold production since 2015) 215k OZs of annual production (2022). Courcy isn’t confined to gold; it’s a treasure trove of critical minerals.
The Mercator gold-bearing corridor became the canvas for Stelmine’s geological artistry, where the company not only uncovered gold deposits but also expanded the corridor’s length substantially through meticulous exploration and leveraging historical data.
Strategic Exploration: Stelmine has secured 100% ownership of 1,815 claims, spanning 933 km² in Northern Quebec’s gold-rich regions.
Leadership in Focus: The recent appointment of Christian de Saint-Rome as interim President and CEO brings over 25 years of international mining and capital markets experience to the helm.
Key Projects: The Courcy and Mercator Projects are at the forefront of Stelmine’s exploration efforts, with significant potential to unlock new gold reserves in under-explored areas.
Real-World Relevance
Stelmine Canada’s contributions to the gold exploration industry are not just theoretical—they have tangible implications. For example, the Courcy Project’s potential to unearth new gold deposits could significantly impact the local economy in Northern Quebec, bringing jobs and infrastructure development to remote areas.
Looking Ahead with Stelmine Canada
As the gold market continues its upward climb, Stelmine Canada is well-positioned to take advantage of the favorable conditions. With a focus on expanding its exploration activities and a leadership team equipped with extensive industry experience, Stelmine is set to play a crucial role in the next phase of gold discovery in Northern Quebec. Investors looking for opportunities in the small-cap space should keep a close eye on Stelmine’s progress as it navigates this promising landscape.
Conclusion:
In a market where gold is hitting new highs, Stelmine Canada emerges as a compelling player, aligning its strategic initiatives with industry growth. As the company continues to explore and develop new opportunities, Stelmine Canada remains a key participant in the industry’s evolving narrative.
This record is published on behalf of the featured company or companies mentioned (Collectively “Clients”), which are paid clients of Agora Internet Relations Corp or AGORACOM Investor Relations Corp. (Collectively “AGORACOM”)
AGORACOM.com is a platform. AGORACOM is an online marketing agency that is compensated by public companies to provide online marketing, branding and awareness through Advertising in the form of content on AGORACOM.com, its related websites (smallcapepicenter.com; smallcappodcast.com; smallcapagora.com) and all of their social media sites (Collectively “AGORACOM Network”) . As such please assume any of the companies mentioned above have paid for the creation, publication and dissemination of this article / post.
You understand that AGORACOM receives either monetary or securities compensation for our services, including creating, publishing and distributing content on behalf of Clients, which includes but is not limited to articles, press releases, videos, interview transcripts, industry bulletins, reports, GIFs, JPEGs, (Collectively “Records”) and other records by or on behalf of clients. Although AGORACOM compensation is not tied to the sale or appreciation of any securities, we stand to benefit from any volume or stock appreciation of our Clients. In exchange for publishing services rendered by AGORACOM on behalf of Clients, AGORACOM receives annual cash and/or securities compensation of typically up to $125,000.
Facts relied upon by AGORACOM are generally provided by clients or gathered by AGORACOM from other public sources including press releases, SEDAR and/or EDGAR filings, website, powerpoint presentations. These facts may be in error and if so, Records created by AGORACOM may be materially different. In our video interviews or video content, opinions are those of our guests or interviewees and do not necessarily reflect the opinion of AGORACOM.
From time to time, reference may be made in our marketing materials to prior Records we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.
NO INVESTMENT ADVICE
This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell products or securities.
You understand and agree that no content in this record or published by AGORACOM constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person and that no such content is tailored to any specific person’s needs. We will never advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.
Neither the writer of this record nor AGORACOM is an investment advisor. Both are neither licensed to provide nor are making any buy or sell recommendations. For more information about this or any other company, please review their public documents to conduct your own due diligence.
Posted by Paul Nanuwa
at 10:11 AM on Monday, April 1st, 2024
In a landscape where gold’s allure shines brighter than ever, Stelmine Canada (TSXV: STH) emerges in a prominent position of strategic brilliance. As the world watches the price of gold soar, Stelmine’s trajectory aligns seamlessly with the industry’s optimistic outlook, propelled by groundbreaking discoveries and visionary milestones.
Industry Outlook and Stelmine Canada’s Trajectory
As investor interest in gold reaches new heights amidst economic uncertainties, Stelmine Canada stands at the forefront of this burgeoning trend. The recent surge in gold prices, driven by a myriad of factors including geopolitical tensions and inflationary concerns, sets the stage for Stelmine’s strategic initiatives to shine even brighter.
Voices of Authority
Industry experts echo Stelmine Canada’s strategic direction, emphasizing the enduring appeal of gold in times of uncertainty. Matt Willer of Phoenix Capital Group Holdings highlights gold’s role as a safety play amid global uncertainty, aligning with Stelmine’s focus on exploring new frontiers amidst economic turbulence.
Stelmine Canada’s FLASH Highlights
Within Stelmine’s portfolio, the Courcy Property emerges as a testament to the company’s commitment to innovation and discovery. From the dazzling Minuapan marvel to Baloo’s encore of success, Courcy embodies the spirit of exploration and potential, setting new standards for gold development in Northern Quebec. Courcy hosts Geological similarities to Newmont’s Eleonore mine (Gold production since 2015) 215k OZs of annual production (2022). Courcy isn’t confined to gold; it’s a treasure trove of critical minerals.
The Mercator gold-bearing corridor became the canvas for Stelmine’s geological artistry, where the company not only uncovered gold deposits but also expanded the corridor’s length substantially through meticulous exploration and leveraging historical data.
Real-world Relevance
Translating Stelmine Canada’s contributions into relatable impacts, one can liken Courcy’s significance to a treasure trove waiting to be unearthed. Just as gold provides stability amid economic turmoil, Stelmine’s strategic endeavors offer investors a rare opportunity to partake in the excitement of discovery and growth.
Looking Ahead with Stelmine Canada
Looking ahead, Stelmine Canada’s vision extends far beyond the confines of the present. With eyes set on unlocking new frontiers and capitalizing on industry trends, Stelmine is poised to continue its journey of innovation and success, reshaping the landscape of gold exploration in the process.
In conclusion, as gold’s price continues its upward trajectory, Stelmine Canada emerges as a compelling player in the industry’s growth narrative. With a portfolio brimming with promise and a vision that transcends the status quo.
This record is published on behalf of the featured company or companies mentioned (Collectively “Clients”), which are paid clients of Agora Internet Relations Corp or AGORACOM Investor Relations Corp. (Collectively “AGORACOM”)
AGORACOM.com is a platform. AGORACOM is an online marketing agency that is compensated by public companies to provide online marketing, branding and awareness through Advertising in the form of content on AGORACOM.com, its related websites (smallcapepicenter.com; smallcappodcast.com; smallcapagora.com) and all of their social media sites (Collectively “AGORACOM Network”) . As such please assume any of the companies mentioned above have paid for the creation, publication and dissemination of this article / post.
You understand that AGORACOM receives either monetary or securities compensation for our services, including creating, publishing and distributing content on behalf of Clients, which includes but is not limited to articles, press releases, videos, interview transcripts, industry bulletins, reports, GIFs, JPEGs, (Collectively “Records”) and other records by or on behalf of clients. Although AGORACOM compensation is not tied to the sale or appreciation of any securities, we stand to benefit from any volume or stock appreciation of our Clients. In exchange for publishing services rendered by AGORACOM on behalf of Clients, AGORACOM receives annual cash and/or securities compensation of typically up to $125,000.
Facts relied upon by AGORACOM are generally provided by clients or gathered by AGORACOM from other public sources including press releases, SEDAR and/or EDGAR filings, website, powerpoint presentations. These facts may be in error and if so, Records created by AGORACOM may be materially different. In our video interviews or video content, opinions are those of our guests or interviewees and do not necessarily reflect the opinion of AGORACOM.
From time to time, reference may be made in our marketing materials to prior Records we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.
NO INVESTMENT ADVICE
This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell products or securities.
You understand and agree that no content in this record or published by AGORACOM constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person and that no such content is tailored to any specific person’s needs. We will never advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.
Neither the writer of this record nor AGORACOM is an investment advisor. Both are neither licensed to provide nor are making any buy or sell recommendations. For more information about this or any other company, please review their public documents to conduct your own due diligence.
Posted by AGORACOM
at 12:00 PM on Monday, January 6th, 2020
SPONSOR: Applied BioSciences is a vertically integrated company focused on the development and commercialization of novel, science-driven, synthetic cannabinoid therapeutics / biopharmaceuticals that target the endocannabinoid system to treat a wide-range of diseases across multiple therapeutic areas Click Here for More Info
If you have been studying cannabis products in depth to find out that
one full-spectrum CBD oil that would suit all your needs then you’d
have come across the word terpenes. But what are these terpenes, or as
others refer them, terpenoids?
Of course, if you are looking to buy CBD, you would be aware of what
cannabinoids are. these are compounds found in the cannabis plants, hemp
and marijuana. So now you have two terms cannabinoids and terpenoids –
but what’s the difference between the two? let’s take a look at this
below:
Cannabinoids
Cannabinoids like cannabidiol and tetrahydrocannabinol have
therapeutic properties. They interact with the natural endocannabinoid
system in your body. What they basically do is that they control the
functionality of cells – this means they manage cell signaling.
Cannabinoids regulate the receiving, processing, and sending of
messages between cells. A cannabinoid like CBD can interact with
cannabinoid receptors in the ECS and regulate your mood, anxiety,
inflammatory response, and much more.
While THC and CBD are the most popular cannabinoids that have studies
supporting their effects, there are hundreds of other cannabinoids too.
These include CBG and CBN among others. All cannabinoids come with
distinct features.
Terpenes
Terpenes or terpenoids are aromatic molecules not only found in
cannabis but in several other plants as well. These as well have
therapeutic properties. They are found in fruits as well. Terpenes in
the lavender flower are responsible for its unique aroma and soothing
properties.
Terpenes also found in citrus fruits and berries too. One terpene
that exists in both cannabis as well as a fruit, mango, is myrcene. The
aroma of weed that many people appreciate comes from this very terpene.
Inside plants, terpenes play a very important role. They protect against
the attack of pests, bacteria and other external agents. The amount and
type of terpenes in cannabis plants varies from one strain to another.
The Entourage Effect
Experts recommend you to go for a full-spectrum CBD formula because
it contains cannabinoids as well as terpenes. Cannabinoids and
terpenoids work together to provide better benefits. They have an
entourage effect together which enables you to get better result sooner.
This is because like cannabinoids, terpenes also have health profiting
qualities.
For instance, some terpenes have an anti-inflammatory nature while
others are great for stress relief. As you may already be aware, CBD
also provides these benefits. Of course, when in combination with other
compounds that have similar properties benefits that you drive are more.
Verdict
Cannabinoids and terpenes are compounds found in the cannabis plant. Both have therapeutic properties but are different. Terpenes are aromatic molecules responsible for the flavor of a plant and fragrance. Cannabinoids interact with the ECS of the body. Together they work even better which is why full-spectrum CBD is revered more than CBD isolate.
Posted by AGORACOM
at 8:37 AM on Wednesday, December 18th, 2019
Trace Analytics Inc. is a leading scalable
analytics cannabis/cannabinoid laboratory poised to meet the demands for
mandated regulatory cannabis/cannabinoid testing
WSDA contracted Trace Analytics for the purpose of doing
cannabinoid profiling for the State’s industrial hemp program to ensure
the percentages of certain cannabinoids are below Federal limits
Applied BioSciences Corp.
(OTCQB:APPB) (“Applied” or the “Company”), today announced that the
Washington State Department of Agriculture (WSDA) has extended its
contract for services with Applied’s majority owned subsidiary, Trace Analytics Inc. (“Trace”).
The WSDA contracted Trace beginning in July 2019 for the testing of
Industrial Hemp samples and percentage testing for delta
9-tetrahydrocannabidiol (THC) and delta 9-tetrahydocannabinolic acid
(THC-A) to ensure the percentages of certain cannabinoids are below
Federal limits.
“We are grateful for our relationship with the WSDA and are pleased
to continue cannabinoid profiling for the WSDA’s Industrial Hemp
program. The testing and reporting of results that we have conducted to
date have demonstrated the quality of our analytics and our dedication
to ensuring compliance with Federal limits,” stated Jason Zitzer, Chief
Operating Officer of Trace Analytics. “We provide expert consulting
services to government entities at all levels around the world and are
appreciative to WSDA to have been selected as the sole lab to conduct
their testing. This contract extension provides another opportunity
toward establishing a higher quality for cannabis and hemp testing.”
Trace Analytics Inc. is a leading cannabis science and technology
company with significant footprints in lab testing, research and
development and licensing. Trace Analytics was started by a group of
scientists who specialized in analytical chemistry, genetics and
molecular biology, focused on ensuring compliance with public safety
standards and end user safety. Trace Analytics is in the process of
expanding throughout the United States, and globally with the goal of
helping the rest of the world adopt “best practices” in cannabis and
hemp testing. The Company also provides expert consulting services to
legislators and regulators in many countries, states and municipalities
around the world.
Based on Applied BioSciences’ stated strategic corporate shift to
focus on its BioPharma division and the development and
commercialization of novel therapeutics that target the endocannabinoid
system (ECS), the Company is currently evaluating a strategic
transaction of Trace Analytics. Applied is currently in late-stage
discussions and expects to close the transaction by year end.
About Applied BioSciences Corp.
Applied BioSciences is a vertically integrated company focused on the
development and commercialization of novel, science-driven, synthetic
cannabinoid therapeutics / biopharmaceuticals that target the
endocannabinoid system to treat a wide-range of diseases across multiple
therapeutic areas. We also deliver high-quality consumer and OTC
THC-free CBD products that promote overall health and wellbeing as well
as state-of-the-art testing and analytics capabilities to our customers.
For more information, visit appliedbiocorp.com and connect with the Company on Twitter, Facebook and LinkedIn.
Posted by AGORACOM
at 4:06 PM on Tuesday, December 17th, 2019
SPONSOR: Applied BioSciences is a vertically integrated company focused on the development and commercialization of novel, science-driven, synthetic cannabinoid therapeutics / biopharmaceuticals that target the endocannabinoid system to treat a wide-range of diseases across multiple therapeutic areas Click Here for More Info
Some of us consume cannabis for its mind-altering effects, while others
seek symptom relief. But cannabis wouldn’t get us high or have some of
its therapeutic benefits if our bodies didn’t already contain a
biological system capable of interacting with its active chemical
compounds, like THC.
Our
endocannabinoid system does just that. But it isn’t there just to allow
us to enjoy the effects of our favorite strain. It serves a vital
purpose for our health and well-being because it regulates key aspects
of our biology. So, what’s it doing, and how does it work?
Homeostasis: Staying in the Goldilocks zone
To understand the human endocannabinoid system, it’s helpful to know a
little about one of the most fundamental concepts in biology:
homeostasis. And the best way to understand homeostasis is to think of
Goldilocks and the three bears.
That classic fairy tale illustrated the idea that the best outcome
often lies somewhere in the middle, between two extremes. We don’t want
things too hot or too cold, but just right.
Homeostasis is the concept that most biological systems are actively
regulated to maintain conditions within a narrow range. Our body doesn’t
want its temperature to be too hot or too cold, blood sugar levels too
high or too low, and so on. Conditions need to be just right
for our cells to maintain optimum performance, and exquisite mechanisms
have evolved to draw them back to the Goldilocks zone if they move out.
The body’s endocannabinoid system (ECS) is a vital molecular system for
helping maintain homeostasis—it helps cells stay in their Goldilocks
zone.
Key pieces of the endocannabinoid system (ECS)
Because of its crucial role in homeostasis, the ECS is widespread
throughout the animal kingdom. Its key pieces evolved a long time ago,
and the ECS can be found in all vertebrate species.
The three key components of the ECS are:
Cannabinoid receptors found on the surface of cells
Endocannabinoids, small molecules that activate cannabinoid receptors
Metabolic enzymes that break down endocannabinoids after they are used
Cannabinoid receptors
Cannabinoid receptors sit on the surface of cells and “listen†to
conditions outside the cell. They transmit information about changing
conditions to the inside of the cell, kick-starting the appropriate
cellular response.
There are two major cannabinoid receptors: CB1 and CB2. These aren’t
the only cannabinoid receptors, but they were the first ones discovered
and remain the best-studied. CB1 receptors are one of the most abundant
receptor types in the brain. These are the receptors that interact with THC to get people high.
CB2 receptors are more abundant outside of the nervous system, in
places like the immune system. However, both receptors can be found
throughout the body (Figure 1).
Figure 1: Where are CB1 and CB2 receptors located in the body?
The CB1 and CB2 receptors are key players in the endocannabinoid system
(ECS). They are located on the surface of many different types of cells
in the body. Both receptors are found throughout the body, but CB1
receptors are more abundant in the central nervous system, including on
neurons in the brain. In contrast, CB2 receptors are more abundant
outside of the nervous system, including cells of the immune system.
Endocannabinoids
Endocannabinoids are molecules that, like the plant cannabinoid THC,
bind to and activate cannabinoid receptors. However, unlike THC,
endocannabinoids are produced naturally by cells in the human body
(“endo†means “within,†as in within the body).
There are two major endocannabinoids: anandamide and 2-AG (Figure 2).
These endocannabinoids are made from fat-like molecules within cell
membranes, and are synthesized on-demand. This means that they get made
and used exactly when they’re needed, rather than packaged and stored
for later use like many other biological molecules.
Figure 2: Anandamide and 2-AG are the two major endocannabinoids.
Cannabinoids are a class of molecules characterized by their ability to
activate cannabinoid receptors like CB1 and CB2. Anandamide and 2-AG
are the two major endocannabinoids produced naturally in the body. THC
is the psychoactive plant cannabinoid produced by Cannabis. All
three of these cannabinoids can activate the CB1 and CB2 receptors,
although each one has a different potency at each receptor.
Metabolic enzymes
The third piece of the endocannabinoid triad includes the metabolic
enzymes that quickly destroy endocannabinoids once they are used. The
two big enzymes are FAAH, which breaks down anandamide, and MAGL,
which breaks down 2-AG (Figure 3). These enzymes ensure that
endocannabinoids get used when they’re needed, but not for longer than
necessary. This distinguishes endocannabinoids from many other molecular
signals in the body, such as hormones or classical neurotransmitters,
which can persist for many seconds or minutes, or get packaged and
stored for later use.
Figure 3: FAAH and MAGL are the key enzymes of the endocannabinoid system.
Enzymes are molecules that accelerate chemical reactions in the body,
often for breaking down molecules. FAAH and MAGL are key players in the
ECS because they quickly break down endocannabinoids. FAAH breaks down
anandamide, while MAGL breaks down 2-AG. These enzymes break down
endocannabinoids very quickly, but are not effective at breaking down
plant cannabinoids like THC.
The three key components of the ECS can be found within almost every
major system of the body. When something brings a cell out of its
Goldilocks zone, these three pillars of the ECS are often called upon to
bring things back, thus maintaining homeostasis. Because of its role in
helping bring things back to their physiological Goldilocks zone, the
ECS is often engaged only when and where it’s needed. Dr. Vincenzo Di Marzo, Research Director at the Institute of Biomolecular Chemistry in Italy, put it to us this way:
“With the ‘pro-homeostatic action of the ECS’ we mean
that this system of chemical signals gets temporarily activated
following deviations from cellular homeostasis. When such deviations are
non-physiological, the temporarily activated ECS attempts, in a space-
and time-selective manner, to restore the previous physiological
situation (homeostasis).â€
In other words, the ECS helps bring things back to the biological Goldilocks zone.
Below we will consider examples of how the ECS helps maintain
homeostasis in two areas: the firing of brain cells in the nervous
system, and the inflammatory response of the immune system.
Endocannabinoid regulation of brain cell firing
Brain cells (neurons) communicate by sending electrochemical signals
to each another. Each neuron must listen to its partners to decide
whether it will fire off its own signal at any given moment. However,
neurons don’t like to get too much input—there’s a Goldilocks zone. If
they get overloaded by signals, it can be toxic. That’s where
endocannabinoids come in.RelatedHow Does Cannabis Consumption Affect the Brain?
Consider a simplified scenario with one neuron listening to two
others. One of these two neurons might become overactive and send too
many signals to the neuron that’s listening. When that happens, the
neuron that’s listening will make endocannabinoids specifically where
it’s connected to the overactive neuron. Those endocannabinoids will
travel back to the “loud†neuron where they bind to CB1 receptors,
transmitting a signal that instructs it to quiet down. This brings
things back to the Goldilocks zone, maintaining homeostasis (Figure 4).
Figure 3: Endocannabinoid signals regulate how active our brain cells are.
Under normal circumstances (top-left), a given brain cell (neuron) will
get just the right amount of input from its partners—not too much, not
too little. However, some of its partners can become overactive, and
send an excessive number of signals (top-right). The neuron that’s
listening will detect this, and release endocannabinoids that tell the
other neuron to quiet down (bottom). This kind of mechanism helps
maintain homeostasis because it helps prevent neurons from sending out
too many signals.
As the example above illustrates, endocannabinoids travel backwards,
which is why they’re known as retrograde signals. Most of the time,
information flow between neurons is strictly in one direction, from
“sender†neurons that release neurotransmitter signals to “receiverâ€
neurons that listen to those signals. Endocannabinoids allow receiver
neurons to regulate how much input they’re getting, and they do this by
sending retrograde signals (endocannabinoids) back to overactive sender
neurons.
But the brain isn’t the only organ that needs to maintain
homeostasis. Every other system of the body, from the digestive to the
immune system, needs to carefully regulate how its cells are
functioning. Proper regulation is crucial for ensuring survival.
Endocannabinoid regulation of inflammation
Inflammation is a natural protective reaction the immune system has
in response to infection or physical damage. The purpose of inflammation
is to remove pathogens (germs) or damaged tissue. The inflamed area is
produced by fluid and immune cells moving into the area to do the dirty
work and return things to their Goldilocks zone.
It’s important that inflammation be limited to the location of damage
and doesn’t persist longer than needed, which can cause harm. Chronic
inflammation and auto-immune diseases are examples of the immune system
getting activated inappropriately. When that happens, the inflammatory
response lasts too long (which results in chronic inflammation) or gets
directed toward healthy cells (which is known as auto-immunity).RelatedCannabis and Arthritis
In general, endocannabinoids seem to suppress or limit the immune system’s inflammatory signals. Professor Prakash Nagarkatti,
Vice President for Research at the University of South Carolina whose
laboratory studies endocannabinoid regulation of immune responses, told
us how tweaking the ECS might be a good way to treat inflammatory
diseases.
“Most of our research demonstrates that endocannabinoids
are produced upon activation of immune cells and may help regulate the
immune response by acting as anti-inflammatory agents. Thus,
interventions that manipulate the metabolism or production of
endocannabinoids may serve as a novel treatment modality against a wide
range of inflammatory disease.â€
Consider a normal immune response triggered by a bacterial infection.
First, immune cells detect the presence of bacteria and release
pro-inflammatory molecules that tell other immune cells to come and join
the fight. Endocannabinoids get released as well (Figure 4), which also
signal to other immune cells for assistance and likely help limit the
inflammatory response so it isn’t excessive. By tightly regulating
inflammation, the immune system can destroy germs or remove damaged
tissue, and then stop. This prevents excessive inflammation, allowing
cells, and thus the body, to return to the Goldilocks zone.
Figure 4: Endocannabinoids help regulate inflammation.
Under normal conditions (top-left), cells of the immune system patrol
the body, on alert for any intruders, such as bacteria. During a
bacterial infection (top-right), immune cells detect the presence of
bacteria and then release a variety of molecules to help mount a
defensive attack (bottom). These signals include pro-inflammatory
molecules (small circles) that help recruit more immune cells to the
site of infection. Endocannabinoids (small diamonds) also get released,
and likely help regulate the magnitude and extent of this inflammatory
response.
How do plant cannabinoids like THC and CBD interact with the endocannabinoid system?
The reason that plant cannabinoids have psychoactive and medicinal
effects within the body is, in large part, because we have an
endocannabinoid system (ECS) that they can interact with. For example,
THC gets you high because it activates the CB1 receptor within the brain. Endocannabinoids like anandamide also activate CB1.
So why aren’t we constantly high?
A couple big reasons. First, THC doesn’t interact with CB1 receptors
in exactly the same fashion as the body’s natural endocannabinoids.
Second, the metabolic enzymes that quickly break down endocannabinoids
like anandamide don’t work on THC, so THC lingers around for much
longer.
It’s important to remember that molecules like cannabinoids and other
neurotransmitters rarely interact with only one receptor type; they
often interact with many. The plant-based cannabinoid CBD illustrates
this nicely, as it interacts with numerous receptor types
in the brain. So, while plant cannabinoids may activate the same
cannabinoid receptors as endocannabinoids, they will likely interact
with several other receptors and therefore have distinct effects.
CBD is also interesting because it can affect overall levels of
endocannabinoids in the brain, referred to as “endocannabinoid tone.â€
CBD inhibits the FAAH enzyme, which breaks down anandamide. Thus, CBD
can increase anandamide levels by preventing FAAH from breaking it down.
Inhibiting the FAAH enzyme has been shown to be a useful strategy for
treating anxiety disorders, and some of CBD’s anti-anxiety properties may come from its ability to inhibit this enzyme and thereby increase endocannabinoid tone.
Summary
The endocannabinoid system (ECS), comprised of cannabinoid receptors,
endocannabinoid molecules, and their metabolic enzymes, is a crucial
molecular system that the body uses to help maintain homeostasis.
Because of its vital role in making sure that cells and systems remain
in their physiological Goldilocks zone, the ECS is tightly regulated; it
gets deployed exactly when and where it’s needed. However, this doesn’t
mean that activating the ECS, through consumption of cannabis or by any
other means, will always make things just right.
Like any other complex biological system, the ECS can go awry. “If
deviation from physiological homeostasis is prolonged, due to either
external factors or chronic pathological conditions, the eCS can lose
its time- and space-selective mode of action and start affecting
inappropriate cells,†Dr. Di Marzo explained. “In these cases, the ECS,
instead of being beneficial, may actually contribute to disease
progression.â€
It’s important to remember that activating the ECS, through cannabis
consumption or by any other means, isn’t a cure-all. Like most of
biology, it’s complicated.
By understanding the biological Goldilocks principle (homeostasis),
and how the ECS illustrates this at the cellular level, we can more
deeply appreciate why we have an ECS to begin with, and how a variety of
cannabis-based therapies might actually work. The presence and critical
function of the ECS across many systems of the body, including the
nervous and immune systems, explains why such a wide variety of ailments
and disease states are responsive to cannabis-based interventions.
References
Gunduz-cinar O, Hill MN, Mcewen BS, Holmes A. Amygdala FAAH and
anandamide: mediating protection and recovery from stress. Trends
Pharmacol Sci. 2013;34(11):637-44. [PDF]
Ligresti A, De petrocellis L, Di marzo V. From Phytocannabinoids to
Cannabinoid Receptors and Endocannabinoids: Pleiotropic Physiological
and Pathological Roles Through Complex Pharmacology. Physiol Rev.
2016;96(4):1593-659. [PDF]
Nagarkatti P, Pandey R, Rieder SA, Hegde VL, Nagarkatti M.
Cannabinoids as novel anti-inflammatory drugs. Future Med Chem.
2009;1(7):1333-49. [PDF]
Pertwee RG. The diverse CB1 and CB2 receptor pharmacology of three
plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and
delta9-tetrahydrocannabivarin. Br J Pharmacol. 2008;153(2):199-215. [PDF]
Wilson RI, Nicoll RA. Endocannabinoid signaling in the brain. Science. 2002;296(5568):678-82. [PDF]
Zlebnik NE, Cheer JF. Beyond the CB1 Receptor: Is Cannabidiol the
Answer for Disorders of Motivation? Annu Rev Neurosci. 2016;39:1-17. [PDF]
Posted by AGORACOM
at 8:46 AM on Wednesday, December 4th, 2019
BioPharma division is focused on the development and
commercialization of novel therapeutics that target the endocannabinoid
system (ECS) –
BioPharma Division focus unlocks opportunities for non-dilutive capital to fund high-value pipeline –
Company seeking to spin-off Applied Products division comprised
of a portfolio of consumer, animal health, women’s health and sports
medicine CBD products –
Majority owned subsidiary, Trace Analytics, in late-stage discussions for a strategic transaction, expected close to year end
Applied BioSciences Corp.
(OTCQB:APPB) (“Applied” or the “Company”), today announced its
strategic corporate shift to fully focus all initiatives and resources
on its BioPharma division and the development of science-driven
biopharmaceuticals that target the endocannabinoid system.
Through its Applied Products
division, the Company currently develops multiple brands offering high
quality health and wellness CBD products that conform to the highest
regulatory standards and markets through established channels in the US.
To date, the Applied Products business unit has seen robust
year-over-year increase in top-line revenue. At this time and with the
understanding that to be successful in the lucrative yet dynamic and
very competitive consumer CBD space would require additional resources
and capital allocations, the Applied Board has made the strategic
decision to allocate all resources moving forward to the BioPharma
business unit.
“After careful consideration, the Board has made
the strategic decision that it is in the best interest of the Company
and our shareholders, to spin off our consumer-facing CBD business,
Applied Products. We believe that this streamlined corporate development
pathway will unlock opportunities for non-dilutive capital to expand
and advance our pipeline of novel therapeutics addressing areas of high
value indications where there remain significant unmet needs,” commented
Dr. Raymond Urbanski, Chief Executive Officer of Applied. “Both our
Trace Analytics and Products business units represent promising
investment opportunities and we are confident that we will be able to
identify the right partners to give each unit the proper share of voice
in this competitive field.”
“Moving forward we see great potential
in our growing BioPharma pipeline. We look forward to continue building
momentum and establishing Applied BioPharma as a leader in the
development and commercialization of innovative therapeutics that target
the endocannabinoid system,” added Dr. Urbanski.
To date, the
Applied BioPharma division has developed partnerships with leading
academic and research institutions and has exclusively licensed
patented, synthetically derived small molecule candidates which target
the endocannabinoid (ECS) G-protein coupled receptors (GPCRs) e.g., the
cannabinoid receptor 1 and cannabinoid receptor 2, for the treatment of
metabolic diseases (type 2 diabetes, obesity, fatty liver disease) and
inflammation (pulmonary inflammation, optic nerve inflammation following
traumatic brain injury and ischemic/reperfusion injury such as acute
kidney injury post-transplant and acute myocardial infarction (heart
attack).
The Company’s growing pipeline is comprised of selective
CB1 and CB2 agonist, inverse agonist and antagonists utilizing multiple
scaffolds and state-of-the-art medicinal chemistry across several
academic centers and institutions. Applied expects to advance the first
of its preclinical programs into open INDs throughout 2020 and its lead
clinical program into a Phase 1 study in early to mid-2020.
The
Company is actively advancing and seeking additional in-license
opportunities with the goal of developing an industry-leading pipeline
of endocannabinoid system-targeted drug candidates that address
significant unmet needs across a wide range of therapeutic areas.
About Applied BioSciences Corp.
Applied
BioSciences is a vertically integrated company focused on the
development and commercialization of novel, science-driven, synthetic
cannabinoid therapeutics / biopharmaceuticals that target the
endocannabinoid system to treat a wide-range of diseases across multiple
therapeutic areas. We also deliver high-quality consumer and OTC
THC-free CBD products that promote overall health and wellbeing as well
as state-of-the-art testing and analytics capabilities to our customers.
For more information, visit appliedbiocorp.com and connect with the Company on Twitter, Facebook and LinkedIn.
Posted by AGORACOM
at 3:57 PM on Wednesday, November 27th, 2019
SPONSOR: Applied Biosciences Corp. is a vertically integrated company focused on the development of science-driven cannabinoid therapeutics and biopharmaceuticals, as well as state-of-the-art testing and analytics. As a leading company in the CBD, Pet and Health and Wellness space, the company is currently shipping to the majority of US states as well as to 5 International countries. Click Here for More Info
A World Health Organization (WHO) report has found no adverse health
outcomes but rather several medical applications for cannabidiol, a.k.a.
CBD, despite U.S. federal policy on this cannabinoid chemical.
According to a preliminary WHO report published last month, naturally
occurring CBD is safe and well tolerated in humans (and animals), and
is not associated with any negative public health effects [PDF].
Experts further stated that CBD, a non-psychoactive chemical
found in cannabis, does not induce physical dependence and is “not
associated with abuse potential.” The WHO also wrote that, unlike THC,
people aren’t getting high off of CBD, either.
“To date, there is no evidence of recreational use of CBD or any
public health related problems associated with the use of pure CBD,”
they wrote. In fact, evidence suggests that CBD mitigates the effects of
THC (whether joyous or panicky), according to this and other reports.
The authors pointed out that research has officially confirmed some positive effects of the chemical, however.
The WHO team determined that CBD has “been demonstrated as an
effective treatment for epilepsy” in adults, children, and even animals,
and that there’s “preliminary evidence” that CBD could be useful in
treating Alzheimer’s disease, cancer, psychosis, Parkinson’s disease, and other serious conditions.
In acknowledgement of these kinds of discoveries in recent years, the
report continued, “Several countries have modified their national
controls to accommodate CBD as a medicinal product.”
But the U.S., the report noted, isn’t one of them.
As a cannabis component, CBD remains classified as a Schedule I
controlled substance, meaning it has a “high potential for abuse” in the
federal government’s view. Nevertheless, the “unsanctioned medical use”
of CBD is fairly common, experts found.
For many CBD users in the U.S., the substance’s mostly unsanctioned
and illegal state creates problems, especially as a wave of online
(mostly hemp) and store-bought CBD oils and extracts have allowed
patients to take the treatment process–and the risks involved in buying
unregulated medicine–into their own hands and homes.
While CBD itself is safe and found to be helpful for many users,
industry experts have warned that not all cannabis extracts are created
equally, purely, or with the same methods of extraction.
And while reports of negative reactions to pure CBD are very few and
far between, researchers are able to say that the cannabinoid wouldn’t
be to blame alone. “Reported adverse effects may be as a result of
drug-drug interactions between CBD and patients’ existing medications,”
they noted.
As the cannabis reform nonprofit NORML
reported, the WHO is currently considering changing CBD’s place in its
own drug scheduling code. In September, NORML submitted written
testimony to the U.S. Food and Drug Administration (FDA) opposing the enactment of in
The FDA, which has repeatedly declined
to update its position on cannabis products despite a large and
ever-growing body of evidence on the subject, is one of a number of
agencies that will be advising the WHO in its final review of CBD.
Perhaps this time around the FDA will listen, and learn something.
The report was presented by the WHO’s Expert Committee on Drug
Dependence, and drafted under the responsibility of the WHO Secretariat,
Department of Essential Medicines and Health Products, Teams of
Innovation, Access and Use and Policy, Governance and Knowledge.
Posted by AGORACOM
at 8:45 AM on Friday, November 15th, 2019
Successfully building BioPharma pipeline in high-value indications
Company plans to advance IND-cleared program into a Phase 1 study in a metabolic disease indication in early 2020
Strategic corporate shift to fully focus on BioPharma Division unlocks opportunities for non-dilutive capital to fund pipeline
Applied BioSciences Corp.
(OTCQB:APPB) (“Applied” or the “Company”), today announced its financial
results for the second quarter Fiscal Year 2020 ended September 30,
2019. The Company also provided an update on its corporate and clinical
progress.
“We continue to push forward on all fronts as we work to establish
Applied as a leader in the development and commercialization of novel,
science-driven, synthetic endocannabinoid therapeutics /
biopharmaceuticals and impact areas of significant unmet need,”
commented Dr. Raymond Urbanski, Chief Executive Officer of Applied.
“Over the course of the past quarter, we have made notable strides on
the corporate and clinical front and remain diligent in working to drive
value for all stakeholders.”
“We continued to build out our BioPharma division and have
established a Scientific Advisory Board of leading experts in the
endocannabinoid space. We were pleased to have welcomed our inaugural
members Judith Korner, M.D. and Patricia Reggio, Ph.D., who will play an
integral role as we look to optimize our therapeutic pipeline and look
to make additional appointments in the near term to help drive this
business unit forward. Additionally, we have continued to execute on our
robust business development initiatives and remain in late-stage
discussions to in-license our product candidates that we believe have
the potential to address a number of areas with significant unmet need.
In tandem, we continue to remain opportunistic in accessing the
necessary non-dilutive funding and capital through strategic investments
from which we believe will provide us with the foundation and momentum
to move forward.”
Applied BioPharma: developing
science-driven synthetic cannabinoid therapeutics that satisfy unmet
medical needs and continue to drive innovation in the endocannabinoid
space.
The Applied BioPharma division is focused on the development and
commercialization of novel therapeutics that target the endocannabinoid
system (ECS).
Applied Biopharma has to date developed partnerships with leading
academic and research institutions and has exclusively licensed
patented, synthetically derived small molecule candidates which target
the ECS G-protein coupled receptors (GPCRs) e.g., the cannabinoid
receptor 1 and cannabinoid receptor 2, for the treatment of metabolic
diseases (type 2 diabetes, obesity, fatty liver disease) and
inflammation (pulmonary inflammation, optic nerve inflammation following
traumatic brain injury and ischemic/reperfusion injury such as acute
kidney injury post-transplant and acute myocardial infarction (heart
attack).
The Company’s growing pipeline is comprised of selective CB1 and CB2
agonist, inverse agonist and antagonists utilizing multiple scaffolds
and state-of-the-art medicinal chemistry across several academic centers
and institutions.
Applied expects to advance the first of its preclinical programs into open INDs in 2020.
ABP-1902, its lead CB2 agonist, intended for mitigating the deleterious effects of ischemic-reperfusion injury.
ABP-1901, its lead CB2 inverse agonist, which has demonstrated
effectiveness in limiting or reversing damage due to neuroinflammation.
Applied expects to advance the first of its clinical programs into a Phase 1 study in early to mid-2020.
The Company is actively advancing and seeking additional in-license
opportunities with the goal of developing an industry-leading pipeline
of endocannabinoid system-targeted drug candidates that address
significant unmet needs across a wide range of therapeutic areas.
Applied Products: portfolio
of consumer, animal health, women’s health and sports medicine of
hemp-derived, THC-free, pharmaceutical grade CBD isolates and
distribution products, all of which ship to the majority of U.S., as
well as to multiple non-U.S. countries.
The Applied Products business unit is focused on maximizing top-line
revenue through selective investments in product lines and marketing
campaigns (increase share-of-voice), continually reevaluating the
endocannabinoid Health & Wellness environment for opportunities and
developing and implementing a nutraceutical strategy.
Applied Products has seen a modest year-over-year increase in top
line revenue. At this time the Board, with the understanding that to be
successful in the lucrative yet dynamic and very competitive consumer
CBD space would require significant resource and capital allocations, is
evaluating various strategic options for this business unit.
Trace Analytics, Inc:
Applied’s majority owned subsidiary scalable analytics
cannabis/cannabinoid laboratory poised to meet the demands for mandated
regulatory cannabis/cannabinoid testing.
In July 2019, Trace Analytics was contracted for services with the
Washington State Department of Agriculture (WSDA). This contract
includes testing Industrial Hemp samples and include percentage testing
for post-decarboxylation delta 9-tetrahydrocannabidiol (THC) and delta
9-tetrahydocannabinolic acid (THC-A) to ensure the percentages of
certain cannabinoids are below Federal limits.
Applied is currently in late-stage discussions for a strategic transaction, expected to close by year end.
Upcoming Milestones Expected to Drive Value
Finalize the in-licensing of product candidates to build pipeline for the Applied BioPharma division.
Closing on the sale of Trace Analytics leading to the infusion of non-dilutive capital into the company.
Finalize and execute on the strategic options for Applied Products.
Successfully execute overall strategy of the Company and business development efforts.
Engage with key stakeholders in the investment community and execute on the robust effort to raise awareness of the Company.
Uplist to a National Exchange.
Summary of Financial Results for Second Quarter FY2020 Ended September 30, 2019
For the quarter ended September 30, 2019, the Company reported net
loss of approximately $777,746 or net loss per diluted share of $0.06,
compared to a net loss of approximately $110,423 or a net loss per
diluted share of $0.01, for the quarter ended September 30, 2018.
The Company reported revenues from Applied BioSciences’ CBD product
lines was $169,654 and $59,400 during the six months ended September 30,
2019 and 2018, respectively. The increase reflects higher sales across
all of the Company’s CBD brand product lines, most notably in its
topical products, combined with expansion into sales of bulk hemp seed
and raw CBD. Service revenue resulting from the Company’s lab testing is
attributed solely to the acquisition of Trace Analytics in January
2019, and totaled $286,077 for the six months ended September 30, 2019.
General and administrative expenses increased $519,140 to $707,192
for the three months ended September 30, 2019 as compared to $188,052
for the three months ended September 30, 2018. The increase was mainly
attributable to the acquisition of Trace Analytics and addition of our
Applied BioPharma subsidiary, with general and administrative expenses
for the remainder of the Company.
The Company ended the quarter with $73,412 in cash and cash
equivalents. The Company is actively evaluating opportunities to fund
continued growth in its products and services revenue along with planned
business development activities for Applied BioPharma and anticipates
closing a financing by the end of first quarter Fiscal Year 2020.
About Applied BioSciences Corp.
Applied BioSciences is a vertically integrated company focused on the
development and commercialization of novel, science-driven, synthetic
cannabinoid therapeutics / biopharmaceuticals that target the
endocannabinoid system to treat a wide-range of diseases across multiple
therapeutic areas. We also deliver high-quality consumer and OTC
THC-free CBD products that promote overall health and wellbeing as well
as state-of-the-art testing and analytics capabilities to our customers.
For more information, visit appliedbiocorp.com and connect with the Company on Twitter, Facebook and LinkedIn.
Posted by AGORACOM
at 2:30 PM on Thursday, November 14th, 2019
SPONSOR: Applied Biosciences Corp. is a vertically integrated company focused on the development of science-driven cannabinoid therapeutics and biopharmaceuticals, as well as state-of-the-art testing and analytics. As a leading company in the CBD, Pet and Health and Wellness space, the company is currently shipping to the majority of US states as well as to 5 International countries. Click Here for More Info
The National Community Pharmacists Association (NCPA) has launched a new resource for pharmacists looking to understand and purchase reliable cannabidiol (CBD) products, called the NCPA CBD Source.
The online resource features CBD products that have been tested for concentrations of all cannabinoids, including CBD and tetrahydrocannabinol (THC), by an independent, third-party lab. The site also features experts that pharmacists can contact with questions regarding buying, selling, and marketing. In addition, pharmacists will be able to evaluate each company included in the resource, as well as see each company’s products.
CBD products have exploded in recent months following the Hemp Farming Act of 2018, which removed hemp from the list of Schedule I controlled substances. According to a statement from NCPA, the United States CBD industry grew by nearly 40% in 2017, and is expected to reach $22 billion by 2024.
CBD can help relieve pain and inflammation resulting from chronic illnesses, as well as boost the immune system, and these effects have led to a flood of patient interest.
“Many pharmacies are deciding to sell CBD products because of the patient demand and because, as the medication expert, they can serve as the source of truth,†said NCPA CEO B. Douglas Hoey, RPh, MBA.
Carter High, PharmD, of Best Value Rhome Pharmacy, said he plans on using the service to bolster the knowledge and products that he already trusts. CBD products are new to the pharmacy wheelhouse, High said, and he gets many phone calls with sales pitches from various CBD companies.
“It gets a little confusing as to whether or not they’re just talking a really good sales pitch, or if they really do have a genuine product,†High said.
High said it’s important for pharmacists to make sure they understand the uses and mechanisms of CBD products, but that this can be challenging given the crowded marketplace.
“Understanding just how CBD affects the body is a very good avenue for a pharmacist to delineate themselves as a knowledge expert on a new upcoming way of how to help patients out,†High said. “A marketplace such as [NCPA CBD Source] fills a very big gap that was missing, and helps from an efficiency standpoint at the store level.â€
While he is excited to use the resources provided, High did emphasize that it doesn’t relieve pharmacists of the responsibility to ensure that the products are reliable, safe, and right for each patient. It does, however, help reassure pharmacists that the decisions they are making are the right ones, he added.
REFERENCE
NCPA, PRS Launch First-of-its-Kind “CBD Source†Tool for Pharmacists
Posted by AGORACOM
at 4:24 PM on Thursday, October 31st, 2019
SPONSOR: Applied Biosciences Corp. is a vertically integrated company focused on the development of science-driven cannabinoid therapeutics and biopharmaceuticals, as well as state-of-the-art testing and analytics. As a leading company in the CBD, Pet and Health and Wellness space, the company is currently shipping to the majority of US states as well as to 5 International countries. Click Here for More Info
Despite the tremendous growth of CBD in the pet space, many consumers
are struggling to understand when, how or even if they should give CBD
to their pets. For those who have made the decision to give CBD to their
pets, there’s an increasing need to learn what’s actually in the CBD
products they buy, including how much CBD is really in them.
Unfortunately, there’s not a lot of solid, accurate information out
there for consumers to rely upon, and not every CBD product manufacturer
makes finding product information easy for consumers. Therefore,
retailers who sell CBD products or find themselves advising customers
about CBD need to thoroughly investigate products before providing that
advice. Additionally, those who sell CBD need to be able to reassure
their customers about the CBD content of the products they supply.
In a recent television news interview on KRIS-TV, the NBC affiliate
in Corpus Christi, Texas, veterinarian Dr. Wallace Graham said, “There
are a lot of people getting in the business because it’s a way to make a
lot of money quick because people are demanding it. My advice to people
that ask me about using CBD and their pets is to buy it from a source
that has a third-party or FDA analysis of their product. That needs to
be an ongoing kind of thing so their products are tested from time to
time so that it is established that they have in them what they say.â€
Graham also said that although the FDA doesn’t regulate CBD products,
when they’re tested by the FDA, “Many of these products, they have found
that they have little or no CBD in them, actually.â€
Chelsea Rivera, head of content for HonestPaws.com, agrees.
“Unfortunately, there are many unscrupulous companies that are not being
upfront about the contents of their products,†she said. “For that
reason, it is imperative that the buyer beware. From the start, we
wanted to establish ourselves as an honest, transparent company that is
on the side of the buyer. It’s even in our name.â€
HonestPaws.com provides consumers with COA, or Certificate of
Analysis, for their products right on their website. A COA is a document
from an accredited laboratory that shows the quantity of various
cannabinoids in a product. HonestPaws.com provides not only product
information but COA for specific batches of products that have been sent
to a lab for testing. Such laboratory analysis and certification is
designed to protect customers and provide proof that each of the
products have the amount of CBD in them that they advertise.
When asked why it is so important to HonestPaws.com to provide this information so readily to their customers, in addition to providing their customers peace of mind, Rivera said, “We hope to be an example in the CBD space to other companies. It’s hard for other companies to deny a consumer their COA when there are companies like Honest Paws who encourage their customers to ask for it.â€
